Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495940 | 0.92 | MEN1 (0.43) | POLBTP53LMNA | |
| SCHEMBL3495640 | 0.78 | IDO1 (0.38) | POLBTP53LMNAFSCN1 | |
| SCHEMBL4964868 | 0.78 | CYP19A1 (0.39) | POLBTP53LMNATHRB | |
| SCHEMBL4965332 | 0.78 | CACNB4 (0.46) | POLBLMNA | |
| SCHEMBL14302885 | 0.77 | ALDH1A1 (0.37) | POLBTP53FSCN1THRB | |
| SCHEMBL3494652 | 0.77 | CACNB4 (0.40) | POLBTHRBPRKAA2 | |
| SCHEMBL3496066 | 0.77 | CACNB4 (0.40) | ENPP2 | |
| SCHEMBL3496366 | 0.77 | HDAC1 (0.38) | POLBTP53LMNATHRB | |
| SCHEMBL3495130 | 0.76 | KMT2A (0.43) | TP53LMNAENPP2L3MBTL1 | |
| SCHEMBL3497512 | 0.76 | TP53 (0.45) | POLBTP53FSCN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | claimed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | claimed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | claimed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC | 2010-06-03 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692014-B2 | Inhibitors of the HIV integrase enzyme | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873155-A1 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1751157-B1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1751157-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005103051-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277661-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | POLB 34/4885TP53 537/4885LMNA 3259/4885 |
| US-20100137283-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | POLB 34/4885TP53 537/4885LMNA 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.